Surgical Repair of Middle Compartment Prolapse (Vaginal Vault or Uterine Prolapse) With or Without Cystocele Clinical Trial
Official title:
Safety and Efficacy of a Transvaginal Suture Capturing Mesh Device: The Nordic Uphold LITE Trial
Verified date | March 2013 |
Source | Karolinska Institutet |
Contact | n/a |
Is FDA regulated | No |
Health authority | Sweden: Institutional Review Board |
Study type | Interventional |
To perform a clinical safety and efficacy assessment of the Uphold LITE system for pelvic organ prolapse in a prospective multicenter, single cohort study.
Status | Completed |
Enrollment | 214 |
Est. completion date | |
Est. primary completion date | March 2013 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - 18 years of age or older and present with primary or recurrent prolapse of the middle vaginal compartment corresponding to stage 2 or higher (according to the Pelvic Organ Prolapse Quantification [POP-Q] system)9, - with or without anterior vaginal wall prolapse, and - experiences symptoms of vaginal bulging with or without a previous hysterectomy - being able to provide oral and written informed consent before entering the study. Exclusion Criteria: - previous cancer of any pelvic organ, - systemic glucocorticoid treatment, - insulin-treated diabetes, - an inability to participate in study follow-up or to provide informed consent, or - the need for any concomitant pelvic surgery. |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Karolinska Institutet | Stockholm County Council, Karolinska Institutet research foundations, Swedish Society of Medicine, Boston Scientific |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Immediate and delayed complications related to the surgical procedure | Serious surgical complications are categorised as any surgical event which is potentially life-threatening, internal organ perforation (or other injury), bleeding in excess of 1000 mL or adverse events, related to the surgical procedure, during follow-up which requires re-hospitalisation. | 1 year | Yes |
Secondary | Pelvic Organ Prolapse Quantification system | The secondary efficacy outcome is a composite of objective and subjective measures including POP-Q stage 0 or 1 of the upper vaginal segment (i.e., point C/D, which represents the most distal point of the vaginal apex in relation to the total vaginal length) and a negative response to the question, "Do you experience a feeling of bulging or protrusion in the vaginal area?" (question 16 on the UDI). The secondary outcome measures further include the individual components of the composite end point, other POP-Q measurements and patient-reported urogenital distress. | 1 year | No |